Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th
Coherus BioSciences (Nasdaq: CHRS) will announce its third-quarter 2021 financial results after the market closes on November 8, 2021. A conference call and webcast will follow at 5 p.m. ET, where management will discuss the results and provide a business update. Investors can access the financial results via the company's website after the announcement. Additionally, the conference call can be joined through specified dial-in numbers and a conference ID. Coherus aims to enhance access to cost-effective medicines for impactful patient care.
- None.
- None.
REDWOOD CITY, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2021 financial results will be released after market close on Monday, November 8, 2021. Starting at 5 p.m. ET, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
After releasing third quarter financial results, the Company will post them on the Coherus website at https://investors.coherus.com.
Conference Call Information
When: Monday, Nov. 8, 2021, starting at 5 p.m. ET
Dial -in: (844) 452-6826 (Toll-Free U.S. and Canada) or (765) 507-2587 (International)
Conference ID: 1838568
Webcast: https://investors.coherus.com/upcoming-events
Please dial-in 15 minutes early to ensure a timely connection to the call.
About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. For additional information, please visit www.coherus.com.
Coherus Contact Information:
Cheston Turbyfill
Coherus BioSciences, Inc.
IR@coherus.com
FAQ
When will Coherus BioSciences release its Q3 2021 financial results?
What time is the conference call for Coherus BioSciences Q3 2021 results?
How can I access the Q3 2021 financial results for Coherus BioSciences?